Trung Huynh
Stock Analyst at UBS
(4.71)
# 161
Out of 5,048 analysts
54
Total ratings
67.57%
Success rate
29.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $194 → $223 | $186.23 | +19.74% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $2.10 | +1,090.48% | 3 | Aug 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,050 → $895 | $896.53 | -0.17% | 9 | Aug 8, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $296.30 | +6.99% | 6 | Aug 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $560 → $584 | $642.25 | -9.07% | 4 | Jul 11, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $24.75 | +53.54% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $24.66 | +1.38% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $46.02 | +17.34% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $3.01 | +132.56% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $6.88 | +88.95% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $186.26 | -6.05% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $82.49 | +52.75% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $211.96 | -19.80% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.43 | - | 1 | Mar 23, 2021 |
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $186.23
Upside: +19.74%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $2.10
Upside: +1,090.48%
Eli Lilly and Company
Aug 8, 2025
Maintains: Buy
Price Target: $1,050 → $895
Current: $896.53
Upside: -0.17%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $296.30
Upside: +6.99%
Regeneron Pharmaceuticals
Jul 11, 2025
Maintains: Neutral
Price Target: $560 → $584
Current: $642.25
Upside: -9.07%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $24.75
Upside: +53.54%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $24.66
Upside: +1.38%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $46.02
Upside: +17.34%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $3.01
Upside: +132.56%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $6.88
Upside: +88.95%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $186.26
Upside: -6.05%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $82.49
Upside: +52.75%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $211.96
Upside: -19.80%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $9.43
Upside: -